India, May 21 -- Picard Medical, Inc. (PMI), the parent company of SynCardia Systems, LLC, the maker of the world's first and only commercially approved Total Artificial Heart or TAH, reported financial results for the first quarter ended March 31, 2026, reflecting a wider net loss despite 85% revenue growth compared to the prior year.
Meanwhile, the firm is preparing plans to regain compliance with the NYSE in response to the notice it received earlier this month.
Following the news, PMI is currently down 5.07% at $0.14.
Company Profile
SynCardia develops, manufactures, and commercialises the SynCardia Total Artificial Heart (STAH), an implantable system that assumes the full functions of a failing or failed human heart.
It is the fir...